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Risk factors of cycle acceleration in acutely
admitted patients with bipolar disorder
Finseth PI, Morken G, Malt UF, Andreassen OA, Vaaler AE. Risk
factors of cycle acceleration in acutely admitted patients with bipolar
disorder.
Objective: To identify risk factors associated with cycle acceleration
(CA), that is, progressive decrease in duration of syndrome-free
intervals between aﬀective episodes, in acutely admitted patients with
bipolar disorder (BD).
Method: All patients (n = 210) with BD I (67%) and BD II (33%)
(DSM-IV) acutely admitted to a hospital serving a catchment area were
compared in retrospect with regard to a positive or negative history of
CA. Putative risk factors of CA with a P-value <0.05 in uni-variate tests
were secondly entered into a logistic regression model.
Results: The logistic regression model was statistically signiﬁcant
(P < 0.0001) and explained between 45.3% and 60.5% of the variance
of CA status. 83.7% of the cases were correctly classiﬁed with a
sensitivity of 87.2% and a speciﬁcity of 80.4%. Unique signiﬁcant risk
factors of CA were increasing severity of aﬀective episodes (odds ratio
(OR) = 28.8), BD II (OR = 3.3), hypomanic/manic episode induced by
an antidepressant and/or alcohol (OR = 3.3), and female gender
(OR = 3.1).
Conclusion: The clinical factors associated with CA may help targeting
patients with BD with a course aggravation, and are in line with
previously reported neuropathological processes of illness progression.
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Signiﬁcant Outcomes
• Signiﬁcant risk factors of cycle acceleration were increasing severity of aﬀective episodes, Bipolar dis-
order II, hypomanic/manic episode induced by an antidepressant and/or alcohol, and female gender.
Limitations
• The conclusions are limited due to the deﬁnition of cycle acceleration based on self-report and the
naturalistic cross-sectional retrospective study design.
• The risk factors of cycle acceleration may not be representative for other clinical populations than
acutely admitted Bipolar disorder patients.
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Introduction
Bipolar disorder (BD) is characterized by recurrent
episodes of depression and hypomania/mania (1).
BD is one of the leading causes of disability world-
wide (2), and the functional decline correlates with
increasing rates of recurrence (3). Recurrence rates
are required to evaluate the prognosis and treat-
ment of individual patients with BD (4). Cycle
acceleration (CA), deﬁned as progressive decrease
in duration of syndrome-free intervals during the
course of illness, is an unequivocally negative out-
come demonstrated in several studies (5–7). Among
diﬀerent measures of recurrence, CA and potent-
ial risk factors associated to it are essential targets
for assessing and identifying course aggravation of
BD (8).
Predictors or causes of CA are sparsely known,
and several reviews have stated a general under-
recognition of CA in BD (9, 10). It is unclear
whether CA is a natural clinical course in a subset
of patients with BD, an adverse event of treatment
interventions, or a combination of these. CA is
somewhat correlated to rapid cycling, which is
deﬁned by four or more aﬀective episodes in a
12-month period (11), but an important diﬀerence
is the lack of an acceleration or progression crite-
rion in the deﬁnition of rapid cycling. In a recent
report, Baldessarini et al. found no general trend
of CA in a sample of patients with BD I (12). How-
ever, they estimated that approximately 40% of
their patients had an accelerating progressive ill-
ness and noted that these were of special interest to
be evaluated for biological, clinical, and treatment
response diﬀerences. Another study suggested that
CA is associated with current Axis - I comorbidity
(13). A large Danish case register study identiﬁed
CA in 25–35% of patients with BD during their
initial hospitalizations in the course of their illness,
where the estimates varied with diﬀerent computa-
tional methods (7). In this study, female gender
was a signiﬁcant predictor of CA, while marital
status and age at ﬁrst admission were not. Yet
another study detected CA in 52% of consecutive
treatment resistant BD in-patients (6). However,
the factors underlying CA development are still
unknown, and CA has not been investigated in a
catchment area based emergency ward sample.
There is a growing body of evidence implicat-
ing progressive neuropathological processes in
the development of CA (14). These are in line
with observations that originate back to Kraepe-
lin who described a natural course of BD with
progressively increasing frequency of episodes in
some patients (5). His theory was later comprised
in the kindling hypothesis of BD, involving a
sensitization of aﬀective episodes leading to
shorter euthymic intervals as a function of epi-
sode numbers (15). A review of kindling and
recurrence rates in BD supported that kindling-
like phenomena occurred in a subgroup of
patients with BD, and proposed that these may
be characterized by a rapid cycling course, cur-
rent or past use of antidepressants (AD), and
early age at onset of illness (16). The role of AD
in BD is highly debated (17), most notably the
discussion on induction of mania. However, there
is limited knowledge whether AD or other psy-
chopharmacological agents may induce CA (8).
Some reports have described AD-induced CA in
BD (18–23), but to what extent this occurs,
remains uncertain (24).
Aims of the study
The aim of the current study was to identify risk
factors associated with cycle acceleration in a
cohort of acutely admitted patients with bipolar
disorder from one catchment area.
Material and methods
Setting
The Østmarka Psychiatric Department, St. Olavs
Hospital, Trondheim University Hospital, Nor-
way, has a catchment area of 212 000 inhabitants
≥18 years of age. Norwegian acute psychiatric ser-
vices are public and available to everyone free of
charge. All patients with acute psychiatric condi-
tions in the catchment area are admitted to this
department. Acute admission to other psychiatric
hospitals occurs only when inhabitants temporarily
reside outside of the catchment area. The depart-
ment is a partaker in The Bipolar Research And
Innovation Network – Norway (Nor-BRAIN) (25,
26).
Patients
Consecutive patients acutely admitted to the hos-
pital from November 2002 through June 2009
suﬀering from current mania, mixed episode, or
depression were diagnosed with the Structured
Clinical Interview for DSM-IV (SCID-I) by two of
the authors (GM and AEV) (27, 28). These two
psychiatrists had undergone a structured SCID-I
training programme before the inclusions started.
The diagnoses were conﬁrmed in a weekly consen-
sus meeting with participation from at least two
senior psychiatrists, of whom at least one person-
ally had examined the patient. All patients with
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BD I or II (DSM-IV) were asked to participate.
The number of patients refusing inclusion was not
registered, but in a retrospective approximation
they counted <2% of all consecutively admitted
patients with BD. Patients were asked to partici-
pate in the study when they were considered to be
able to give an informed consent, and they were
included only once. The only exclusion criterion
was a non-proﬁciency in English or Norwegian.
Ethics
Written, informed consent was obtained from all
the included patients. The study was approved by
The Regional Committee for Research Ethics,
Central Norway.
Assessments
The patients were interviewed with a Norwegian
adaptation of the Network Entry Questionnaire
(NEQ) developed by the Bipolar Collaboration
Network (29, 30). The NEQ ratings were con-
ducted by a specially trained research nurse or one
of the psychiatrists (GM or AEV). The NEQ has
48 items covering a wide range of demographic
and clinical factors describing the course of the ill-
ness. This included a retrospective assessment of
all current and previous medication the patient has
taken for treatment of BD. CA was assessed by
asking the patients to disclose whether they had
exhibited progressive decrease in duration of syn-
drome-free intervals in the course of their illness.
From this, CA was solely based on the patients’
own judgement and was registered dichotomously
(yes/no). Alcohol and substance use disorders, his-
tory of psychosis, and social and occupational
functioning between episodes the past year, were
deﬁned as recently described by Finseth et al. (31).
Measures of education and disability pension were
deﬁned as described by Schoeyen et al. (26). Early
age at onset of BD is a well known predictor of
poor outcome (32), and was deﬁned as debut of
ﬁrst aﬀective episode ≤18 years based on self-
report (33). Long-term pharmacological treatment
was deﬁned as continuous use of at least one medi-
cation against BD (AD, anticonvulsant, antipsy-
chotic or lithium) for ≥12 months prior to the
index episode.
Statistics
The patients were divided into two groups with
regard to history of CA or not, termed CA and
Non-CA. Risk factors and pharmacological treat-
ment likely to aﬀect recurrence of new aﬀective
episodes were analyzed between the two groups.
The total number of patients with index mixed epi-
sode was low (7 in the CA group and 4 in the Non-
CA group). In the statistical procedures, we chose
to merge these with index episode mania, as in this
setting (Emergency ward), patients with mixed epi-
sode were generally admitted due to symptoms of
mania. Hypomania/mania induced by an AD and
hypomania/mania induced by alcohol were ana-
lyzed both separately and combined. This combi-
nation was also utilized in a recent report from our
research group, where the combined variable of
AD-induced and/or alcohol-induced aﬀective epi-
sodes revealed a signiﬁcantly stronger association
to suicide attempt versus the separate variables
(31). The rationale for this combination was to
assess patients at risk of experiencing hypomanic/
manic episodes induced by biological substances
(34).
Categorical variables were analysed with chi-
square tests. Continuous variables with normal
distribution were analysed with a t-test for inde-
pendent samples. A Mann–Whitney test was used
when assumptions of normal distribution were not
adequately met. The alpha level was set to <0.05.
We did not correct for multiple comparisons but
included all variables with P < 0.05 in the logistic
regression analysis.
All variables from the univariate analysis with
P < 0.05, together with gender and duration of
illness, were entered as independent variables into
a stepwise logistic regression model with CA as
the dependent variable. As recommended when
conducting regression models, gender was also
included (35), although it did not meet the criterion
of P < 0.05. Due to clinical overlap and high inter-
correlations between some independent variables,
there were certain exceptions from the selection of
variables: Rapid cycling was excluded due to the
partial overlap with CA per deﬁnition, as we
wanted to identify the unique predictors of CA.
Time from ﬁrst aﬀective episode to any medication
was excluded due to strong correlation with early
age at onset, which has also been shown before
(25, 36). Duration of illness was included instead
of age at inclusion, as this was considered more
adequate to control for due to the longitudinal
quality of CA. Hospitalizations due to mania were
per deﬁnition occurring only in BD I, and lifetime
diagnosis of psychosis was strongly correlated to
BD I (13% of BD II patients and 63% of BD I
patients with lifetime diagnosis of psychosis respe-
ctively). We thus repeated the univariate analysis
between CA and lifetime diagnosis of psychosis for
the BD I patients only, with a non-signiﬁcant
result. From this, we concluded that the variables
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lifetime diagnosis of psychosis and number of hos-
pitalizations due to mania were better explained by
the variance of BD subtype, and they were there-
fore omitted from the regression model. All covari-
ates were entered in one block with the backward
stepwise method as this was an explorative analysis.
All statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS
Statistics) version 17.0 (SPSS Inc., Chicago, IL,
USA).
Results
A total of 210 patients entered the study. Of them
were 112 women (53.3%). 143 patients (68.1%)
were diagnosed with BD I and 67 (31.9%) with BD
II. Mean age at inclusion for the total sample was
43  14 (SD) years. 100 patients (47.6%) reported
CA in the course of their disorder.
Descriptive analyses of sociodemographic fea-
tures, psychiatric morbidity, psychopharmacologi-
cal treatment and course of illness between the CA
and Non-CA groups are shown in Table 1 and
Table 2.
Clinical factors associated with CA
CA was more frequent in patients with BD II
(P < 0.0001) as well as in patients with index epi-
sode depression (P = 0.002). In an analysis of CA
and BD subtype in the subsample of patients with
index episode depression, there was a non-signiﬁcant
trend of more CA among patients with BD II (per
deﬁnition index episode depression), than in
patients with BD I (CA in BD II 66.2% vs. BD
I 33.8%, v2 = 3.78, df = 1, P = 0.052). A higher
number of hospitalizations due to mania (P <
0.0001) and a life-time diagnosis of psychosis
(P < 0.0001) were both negatively associated with
CA, while the number of hospitalizations due to
depression did not diﬀer between the groups.
The CA group was characterized by a higher
proportion of individuals with early age at onset of
BD (P = 0.002) and a longer delay from onset of
BD to ﬁrst medication against aﬀective symptoms
(P < 0.0001), but not with duration of illness. The
CA group had signiﬁcantly higher number of sui-
cide attempts (P = 0.022). However, the latter
association was no longer signiﬁcant in a separate
logistic regression model between CA and number
of suicide attempts with duration of illness added
as a covariate only.
Hypomanic/manic episode induced by AD and/
or alcohol was signiﬁcantly more frequent in the
CA group (P = 0.003), while the isolated variables
hypomanic/manic episode induced by AD, and
hypomanic/manic episode induced by alcohol
alone were not signiﬁcantly associated with CA.
Patients in the CA group had signiﬁcantly more
prior trials with AD’s (P < 0.0001) and anxio-
lytics/hypnotics (P = 0.027). Long-term use, i.e.
≥12 months, of at least one current psychophar-
macological agent was negatively associated with
CA (P = 0.032). Except these ﬁndings, there were
Table 1. Characteristics of acutely admitted bipolar disorder patients with and without cycle acceleration
Total N*
Cycle acceleration Non-Cycle Acceleration
Statistic† P-valuen = 100 47.6% n = 110 52.4%
Socio-demographic features
Gender, n (%)
Female 210 60 60 52 47 3.41 0.065
Male 40 40 58 53
Age, mean  SD 41 14 44 14 1.89 0.061
Education, some college plus, n (%) 210 29 29 41 37 1.61 0.20
Disability pension, n (%) 210 48 48 52 47 0.01 0.92
Own children, n (%) 210 62 62 70 64 0.06 0.81
Married or cohabitating, n (%) 204 30 31 42 39 1.54 0.21
Psychiatric morbidity
Bipolar disorder I or II, n (%)
BD I 210 56 56 87 79 12.9 <0.0001
BD II 44 44 23 21
Index episode, n (%)
Depression 210 65 65 48 44 9.62 0.002
Mania or mixed 35 35 62 56
Alcohol and/or substance use disorder, lifetime, n (%) 210 28 28 29 26 0.07 0.79
Diagnosis of psychosis, lifetime, n (%) 210 34 34 65 59 13.2 <0.0001
*Statistical analyses were performed for the subsamples in this column due to missing data in some variables.
†Statistic: Contingency tables (v2) and Independent samples t-test (t).
SD, Standard deviation; BD, Bipolar disorder.
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no other diﬀerences in current or prior medication,
and total numbers of prior and current psycho-
pharmacological agents were indiﬀerent between
the CA and Non-CA groups.
The CA group reported more increasing severity
of aﬀective episodes (P < 0.0001) and more rapid
cycling than the Non-CA group (P = 0.008). Dur-
ing the past 12 months before inclusion to the
study, the CA group reported a worse level of
social and occupational functioning between aﬀec-
tive episodes (P = 0.012).
Multi-variate analysis revealed independent effect of several CA
risk factors
The statistically signiﬁcant variables from the
logistic regression model are presented in Table 3.
The ﬁnal step of the backward stepwise logistic
regression model was statistically signiﬁcant with
v² (df = 6, n = 196) = 118.3, P < 0.0001. It explai-
ned between 45.3% (Cox and Snell R square) and
60.5% (Nagelkerke R square) of the variance of
CA status. There was a reasonable sensitivity and
speciﬁcity, as 83.7% of the cases were correctly
classiﬁed with a sensitivity of 87.2% and a speciﬁc-
ity of 80.4%. None of the variables had a variance
inﬂation factor above 2, which was small and sup-
ported a low risk of multicollinearity in the model.
The predictors that made a unique signiﬁcant con-
tribution were (in order of decreasing odds ratio):
increasing severity of aﬀective episodes, BD II,
hypomanic/manic episode induced by an AD and/
or alcohol, and female gender.
Discussion
The present study identiﬁes risk factors related to
CA in a cohort of acutely admitted patients with
BD, including severity of aﬀective episodes, BD II,
hypomanic/manic episode induced by an AD and/
or alcohol, and female gender. These results are in
line with previous ﬁndings of patients with BD
Table 2. Psychopharmacological treatment and course of illness in acutely admitted bipolar disorder patients with and without cycle acceleration
Total N*
Cycle acceleration
Non-Cycle
acceleration
Statistic† P-valuen = 100 47.6% n = 110 52.4%
Current psychopharmacological treatment
Total number of current psychopharmacological agents, median (IQR)‡ 207 3 2–3 3 2–3 0.29 0.77
Current antidepressant, n (%) 210 29 29 30 27 0.08 0.78
Current antipsychotic, n (%) 210 54 54 69 63 1.64 0.20
Current anticonvulsant, n (%) 210 78 78 73 66 3.51 0.06
Current lithium, n (%) 210 12 12 17 16 0.53 0.47
Current anxiolytic/hypnotic, n (%) 210 46 46 45 41 0.55 0.46
At least one psychopharmacological agent ≥12 months, n (%) 210 22 22 39 36 4.60 0.032
Prior psychopharmacological treatment
Total number of prior psychopharmacological agents, median (IQR)‡ 210 2.5 1–5 3 1–4 0.88 0.38
Number of prior antidepressants, median (IQR)‡ 210 1 0–2 0 0–1 3.94 <0.0001
Number of prior antipsychotics, mean (IQR)‡,§ 210 0.77 0–1 1.16 0–2 1.95 0.051
Number of prior anticonvulsants, median (IQR)‡ 210 0 0–0 0 0–1 1.06 0.29
Ever prior Lithium, n (%) 210 17 17 27 24.5 1.80 0.18
Number of prior anxiolytics/hypnotics, mean (IQR)‡,§ 210 0.84 0–1 0.45 0–1 2.21 0.027
Course of illness
Number of hospitalizations due to depression, median (IQR)‡ 190 1 1–2 1 0–2 1.25 0.21
Number of hospitalizations due to mania, median (IQR)‡ 190 0 0–1 1 0–3 3.66 <.0001
Duration of illness (years), mean  SD¶ 205 24 14 21 15 1.37 0.17
Early age of onset (<19 years), any affective symptoms, n (%) 207 68 68 50 47 9.54 0.002
Years from first affective episode to any medication, median (IQR)‡ 192 13 5–20 9 0–14 3.72 <0.0001
Number of suicide attempts (0->4), median (IQR)‡ 209 2 1–2 1 1–2 2.28 0.022
Increasing severity of affective episodes, n (%) 203 87 90 26 25 87.2 <0.0001
Rapid cycling, n (%) 209 22 22 10 9.1 6.93 0.008
Social and occupational functioning between episodes the past year, median (IQR)‡ 209 3.2 2–4 2.8 2–4 2.52 0.012
Hypomanic/manic episode induced by AD and/or alcohol, n (%) 207 34 35 18 17 9.07 0.003
Hypomanic/manic episode induced by AD, n (%) 204 15 16 8 7 3.43 0.064
Hypomanic/manic episode induced by alcohol, n (%) 206 22 22 13 12 3.70 0.054
*Statistical analyses were performed for the subsamples in this column due to missing data in some variables.
†Statistic: Contingency tables (v2), Mann–Whitney (z for two groups) and Independent samples t-test (t).
‡Mann–Whitney test.
§The mean is shown due to equal median values.
¶Independent samples t-test.
IQR, Inter quartile range; SD, Standard deviation; AD, Antidepressant.
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with rapid cycling (37), but have to our knowledge
only sparsely been studied in relation to the quality
of acceleration of subsequent episodes included in
the deﬁnition of CA. Thus, the current risk factors
may be useful in assessing a progressive course of
BD as well in providing clinical entities for future
studies of progressive pathways of recurrence in
BD.
Sociodemographic features were indiﬀerent
between the CA and Non-CA groups, except
female gender being a risk factor of CA in the
logistic regression model. Female gender was, how-
ever, not signiﬁcantly associated with CA in the
univariate analysis, which may have been due to
suppressor eﬀects of unknown confounders in the
univariate analysis, or by more precise estimation
of gender as a predictor in the logistic regression
model due to the presence of another strong pre-
dictor in the model (38). The association between
CA and female gender is concordant with ﬁndings
in the Danish case register study (7). The causative
relation between CA and female gender has never
been investigated, but it is known that also rapid
cycling is more common in women than in men
(39). Reproductive hormones, higher rates of hypo-
thyroidism, and possible diﬀerences in response or
exposure to mood stabilizers and antidepressants
have been hypothesized to account for the
increased risk of rapid cycling in women (40). Fur-
ther studies are needed to identify the underlying
cause of the association between female gender
and CA.
CA was correlated with patient-reported incre-
asing severity of the disorder in the logistic regres-
sion model, which has also been demonstrated
before (6). This indicates that assessment of CA
gives important information of the longitudinal
development of BD. It may seem contradictory
that CA was associated with increasing severity of
the disorder, while not with disability pension. One
possible explanation to this is the relatively long
duration of illness in both groups in this study,
which is known to be associated with unemploy-
ment (41). It should be noted that the CA group
still reported a worse social and occupational func-
tioning between aﬀective episodes the year prior to
study inclusion, however only in the univariate
analysis.
CA was associated with a diagnosis of BD II.
This was further explained in the univariate analy-
sis where CA was associated with index episode
depression and negatively associated with number
of hospitalizations due to mania. Together, this
indicates that CA is a clinical phenomenon more
likely to occur in BD patients with a depressive
dominance, and might be the reason why CA
could not be identiﬁed in a follow-up of patients
with BD I in a recent report (12). Another possible
explanation could be diﬀerent strategies of phar-
macological treatment of BD I vs. BD II.
Our ﬁndings of alcohol and/or AD association
with CA are in line with the hypothesis that AD
and alcohol are involved in stimulating initial
aﬀective episodes in a subgroup of patients who
later develop a sensitized pattern of spontaneous
episodes with a decrease in duration of syndrome-
free intervals (15, 42). This view has been sup-
ported by clinical ﬁndings that AD exposure
predicts long-term mood instability in patients
with BD and loss of AD eﬃcacy after repeated
exposures (43–46). The ﬁndings could also be in
line with the kindling hypothesis (16). This sup-
ports the view that BD is a progressive illness, at
least in a subgroup of severely aﬀected patients,
such as included in the current study. However,
these clinical observations are in contrast to experi-
mental animal evidence suggesting neuroprotective
properties of AD (47). AD induction of hypoma-
nia/mania alone was not signiﬁcantly associated
with CA, which may be a result of the relatively
low frequency of hypomania/mania induced by
AD and the small sample size and thus statistical
power in the current study. Future studies to deter-
mine the direction of the association between CA
and AD treatment are warranted, advocating for
longitudinal studies of the role of AD treatment
and alcohol use in development of CA in BD.
Although not signiﬁcantly associated with CA in
the logistic regression model, it should be com-
mented on some of the associations between CA
and psychopharmacological treatment. The nega-
tive association between CA and use of at least one
current psychopharmacological agent for at least
12 months could be the result of protective eﬀects
of long-term pharmacological treatment for some
patients, but may as well be a selected group of
Table 3. Significant risk factors from the final step of the logistic regression model
based on risk factors with P-value <0.05 in the univariate analysis
B Wald P-value Exp(B)
95% CI for Exp
(B)
Lower Upper
Increasing severity of
affective episodes
3.36 51.41 <0.0001 28.81 11.50 72.20
BD type II (vs I) 1.20 6.04 0.01 3.31 1.27 8.61
Hypomanic/manic episode
induced by AD and/or
alcohol
1.19 5.62 0.02 3.29 1.23 8.79
Female gender 1.13 5.95 0.01 3.08 1.25 7.63
Constant 4.60 33.36 <0.0001 0.010
CI, confidence interval; BD, bipolar disorder; AD, antidepressant.
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patients where the disorder requires fewer needs to
initiate change in medication. The association
between CA and that of currently using an anti-
convulsant might be a result of the clinicians being
aware of CA in these patients, and unlikely to be
caused by anticonvulsants per se. The CA group
had signiﬁcantly more trials with AD, and anxio-
lytics and hypnotics. These ﬁndings might be
linked to the depressive dominance in patients with
CA, but this study does not allow us to conclude
on the direction of these associations.
The CA frequency of 47.6% in our acute ward
sample is in line with the NIMH-study with sever-
ely ill patients resistant for conventional treatment
(6), but higher than the Danish care register study
which conservatively assessed intervals between
hospitalizations only (7). However, our study
design does not allow us to make claims about the
absolute frequency of CA as the assessments were
based on self-report, which is subject to recall bias
and possibly inﬂated reporting due to the inﬂuence
of the current aﬀective episode.
This study has some strengths and limitations.
All acutely admitted patients from one catchment
area were evaluated for inclusion. The sample is
representative, but may not be generalizable to
other clinical settings. A limitation in this study is
the deﬁnition of CA, which was based solely on the
patient’s own judgement and not on the more pref-
erably objective recordings of cycle evolution over
time with a standardized life-chart method. It is
also possible that the self-report data were inﬂu-
enced by a recall bias related to the current aﬀec-
tive episode at inclusion. Consequently this may
have altered the patient’s self-report of CA by con-
fusing CA with other reasons to increase of illness
severity, possibly inﬂating the CA frequency among
patients included with a current depressive episode.
It is however unlikely that a recall bias of CA
should systematically skew the speciﬁc ﬁndings of
risk factors associated with CA. In this case, the
eﬀect of recall bias would more likely result in type
II error. We are limited by the naturalistic, retro-
spective design to conclude on the direction of the
associations, and there may be unknown con-
founding factors not accounted for in the present
analysis. Speciﬁcally, we cannot make inferences
about the direction of eﬀect between CA and
hypomanic/manic episode induced by AD and/or
alcohol. If hypomanic/manic episode induced by
AD and/or alcohol preceded CA, it may be the
result of a biological vulnerability of switching
between mood states in some patients. This ﬁnding
may add to further understanding of neuropro-
gressive pathways of recurrence in BD (14). How-
ever, it is also possible that patients with CA due
to a more depressive dominance of their disorder
were treated more frequently with AD, resulting in
a higher accumulated chance of AD-induced hypo-
mania/mania. The possibility that CA is an intrin-
sic naturally occurring course in some patients as
noted in the prepharmacological era (5), meaning
it would occur independently of pharmacological
treatment, is impossible to correct for due to ethi-
cal considerations.
In conclusion, in this naturalistic, retrospective
study, we found that severity of aﬀective episodes,
BD II, hypomanic/manic episode induced by an
AD and/or alcohol, and female gender are associ-
ated with CA. These putative risk factors of CA
may help targeting patients with BD with a course
aggravation, and they are in line with previously
proposed neuropathological processes of illness
progression. The directions of cause for these risk
factors need to be identiﬁed in longitudinal studies,
preferably diﬀerentiating subgroups of BD and
grade of severity for the broader understanding of
CA.
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